UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

Frontiers in oncology, 2021-02, Vol.10, p.610820-610820

2021

Volltextzugriff (PDF)

Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms

Cancers, 2024-04, Vol.16 (8), p.1563

2024

Volltextzugriff (PDF)

Bone marrow involvement by primary oxalosis

Blood Research, 2020, 55(4), , pp.192-192

2020

Volltextzugriff (PDF)

The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index

Leukemia, 2020-09, Vol.34 (9), p.2451-2459

2020

Volltextzugriff (PDF)

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin

Cancers, 2021-06, Vol.13 (13), p.3214

2021

Volltextzugriff (PDF)

Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients

Supportive care in cancer, 2013-11, Vol.21 (11), p.3179-3189

2013

Volltextzugriff (PDF)

Current treatment of COVID-19 in renal patients: hope or hype?

Internal and emergency medicine, 2020-11, Vol.15 (8), p.1389-1398

2020

Volltextzugriff (PDF)

High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity

International journal of hematology, 2020-08, Vol.112 (2), p.141-146

2020

Volltextzugriff (PDF)

Characteristics and outcome of therapy‐related myeloid neoplasms: Report from the Italian network on secondary leukemias

American journal of hematology, 2015-05, Vol.90 (5), p.E80-E85

2015

Volltextzugriff (PDF)

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

The Lancet. Haematology, 2017-03, Vol.4 (3), p.e127-e136

2017

Volltextzugriff (PDF)

Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment

Cancers, 2022-05, Vol.14 (10), p.2565

2022

Volltextzugriff (PDF)

Correction to: Current treatment of COVID-19 in renal patients: hope or hype?

Internal and emergency medicine, 2021, Vol.16 (1), p.251-251

2021

Volltextzugriff (PDF)

Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study

Scientific reports, 2020-06, Vol.10 (1), p.9156-9156, Article 9156

2020

Volltextzugriff (PDF)

Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach

Frontiers in oncology, 2021-06, Vol.11

2021

Volltextzugriff (PDF)

Impact on mental health, disease management, and socioeconomic modifications in hematological patients during the COVID-19 pandemic in Italy

Therapeutic advances in hematology, 2023-01, Vol.14, p.20406207231190683-20406207231190683

2023

Volltextzugriff (PDF)

PB2033: ADVANCED CHRONIC MYELOMONOCYTIC LEUKEMIA IN ELDERLY AND FRAIL PATIENTS MANAGED BY AZACITIDINE IN THE FIELD OF CLINICAL PRACTICE

HemaSphere, 2023-08, Vol.7 (S3), p.e4005998-n/a

2023

Volltextzugriff (PDF)

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

Blood cancer journal (New York), 2022-09, Vol.12 (9), p.132-132, Article 132

2022

Volltextzugriff (PDF)

The use of major analgesics in patients with renal dysfunction

Current drug targets, 2010-06, Vol.11 (6), p.752-758

2010

Volltextzugriff (PDF)

A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol

Health and quality of life outcomes, 2018-06, Vol.16 (1), p.127-127, Article 127

2018

Volltextzugriff (PDF)

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes

Cancers, 2019-09, Vol.11 (9), p.1373

2019

Volltextzugriff (PDF)

Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform

Frontiers in oncology, 2022-03, Vol.12, p.826040-826040

2022

Volltextzugriff (PDF)

1 – 25 von 325

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(257)
Mit Volltextzugriff
(282)

Publikationsform

Artikel
(288)
Berichte
(37)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms

Bone marrow involvement by primary oxalosis

Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database

The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin

Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

Current treatment of COVID-19 in renal patients: hope or hype?

High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity

Characteristics and outcome of therapy‐related myeloid neoplasms: Report from the Italian network on secondary leukemias

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment

Correction to: Current treatment of COVID-19 in renal patients: hope or hype?

Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study

Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach

Impact on mental health, disease management, and socioeconomic modifications in hematological patients during the COVID-19 pandemic in Italy

PB2033: ADVANCED CHRONIC MYELOMONOCYTIC LEUKEMIA IN ELDERLY AND FRAIL PATIENTS MANAGED BY AZACITIDINE IN THE FIELD OF CLINICAL PRACTICE

Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

The use of major analgesics in patients with renal dysfunction

A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol

Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes

Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform

Suchergebnisse filtern